BioLASCO Taiwan Co., Ltd. (TPEX:6662)

Market Cap	854.16M
Revenue (ttm)	292.50M
Net Income (ttm)	44.03M
Shares Out	25.61M
EPS (ttm)	1.72
PE Ratio	19.40
Forward PE	n/a
Dividend	1.65 (4.95%)
Ex-Dividend Date	Jul 26, 2024

Volume	2,008
Average Volume	11,031
Open	33.10
Previous Close	33.35
Day's Range	33.10 - 33.10
52-Week Range	30.70 - 41.00
Beta	0.32
RSI	49.55
Earnings Date	May 14, 2025

About BioLASCO Taiwan

BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine di...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 91
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6662

Financial Performance

In 2024, BioLASCO Taiwan's revenue was 292.50 million, an increase of 10.49% compared to the previous year's 264.72 million. Earnings were 44.03 million, a decrease of -11.49%.